btlines

DIA GPW mWIG40 Periodic report · PAP Biznes

Diagnostyka SA (DIA) · Q2 2026 results and valuation

Share price: 153.10 zł · 2026-11-10

Diagnostyka SA provides laboratory diagnostics and blood collection services. The company operates a network of laboratories and collection points to serve customers through diagnostic testing. Source: Half-year report (2026-09-10)

Results Q2 2026 vs Q2 2025 · year over year · published 10 Sep 2026 and 4 Sep 2025

Net income down 14.0% year on year. The language turned more cautious.

1 · Numbers

−14.0%

Net income vs Q2 2025

Net income 57.4M vs 66.8M

Revenue +15.7%

2 · How the report reads

More cautious

Language tone vs last period

Report language: upbeat for a company report — more cautious than in Q2 2025.

Weak signal: formal report language, not a call.

3 · What stood out

Diagnostyka SA's organic growth strategy includes implementing artificial intelligence and machine learning technologies, though failure to implement these properly may pose risks to operations.

Valuation

Is Diagnostyka SA undervalued?

Reverse DCF. Free cash flow from the last full fiscal year (2025-12-31), grown for 10 years, discounted back, plus a terminal value. “Implied growth” is the rate the current price assumes.

At 18.9% growth a year (3-year revenue growth), the model's fair value is 239.79 zł a share — the stock trades 36% below it. Today's price assumes 13.3% growth a year.

Current price

153.10 zł

close of 2026-11-10

Market implies growth of iThe yearly free-cash-flow growth, for the next 10 years, that today’s share price already assumes. If you believe the company grows faster than this, the stock is cheap under this model; slower, and it is expensive.

+13.3% for 10 yrs

Fair value / share

239.79 zł

Buy below

179.84 zł

Price vs fair value

Undervalued 36%

Price vs buy-below price

Undervalued 15%

Official channels

The company's own website and social media accounts.

Read between the lines

No major shifts flagged this period.

Tone

How upbeat the language was, compared with other companiesiTone counts positive minus negative finance words, adjusted for length. Executives mostly speak positively, so the labels compare each call with every company's latest call: “typical” is the middle third, “very upbeat” the top tenth, “cautious” the bottom tenth.. Dot: Q2 2026. Ring: Q2 2025.

Report language Upbeat (was very upbeat)

Upbeat for a company report — more cautious than in Q2 2025. Periodic reports carry legally required risk wording, so their tone moves little and is a weak signal.

Sentences that drove the tone
“The Group's organic growth strategy is partly based on the implementation of artificial intelligence and machine learning technologies, while the failure of their implementation or the lack of appropriate procedures and controls may give rise to risks...”
“The Group may be exposed to payment-related risks that could have a material impact on its operations, financial results”
“The Group relies on a strong and recognizable brand, the loss of which, including as a result of adverse customer opinions of the Group, may have a significant adverse impact on the Group's market position, its operations, its situation...”

Full figures

PLN · PAP Biznes report (2026-09-10)

Metric Q2 2026 Q2 2025 Change
Revenue 686.2M 593.4M +15.7%
Operating income 95.1M 102.8M −7.5%
Net income 57.4M 66.8M −14.0%
EPS 1.70 1.89 −10.1%
P/E today 20.1 21.9 30.4 −8.5

Topics

Topics are drawn from the full report text, not management commentary.

Most discussed now

  • The Ordinary General Meeting resolved to pay a dividend by the Company to the Company's shareholders for the year ended December 31, 2021.
  • 1 The Group defines EBITDA as net profit (loss) adjusted for income tax, share in the results of associates or joint ventures
  • Profi lactyka 40PLUS, which generated a significant number of laboratory services.
  • To its core activity in laboratory diagnostics, Diagnostyka is also intensively developing a network of imaging diagnostic facilities.

Faded since Q2 2025

  • Fading The Group generates revenue from the sale of goods (primarily reagents).
  • Fading Under the LTIP-Z incentive program, for the 6-month period ending June 30, 2025, the fair value of the benefits received (the service of…

Latest announcements

Official filings, newest first. Summaries are generated from each filing and its attachment; every figure is checked against the source.

Similar companies

Healthcare · Diagnostics & Research
All Healthcare companies →